GliXogen Therapeutics is developing small molecules to enhance remyelination in neurodegenerative disorders.
Neural stem cells (NSC) that express Gli1 migrate to sites of demyelination where they differentiate into oligodendrocytes that remyelinate nerve axons, and also say NSCs expressing and not NSCs that express. Inhibition of Gli1 was shown to enhance this phenomenon and improve the clinical signs and remyelination in several in vivo models.
Prof. James Salzer, MD, PhD – Inventor
Yair Fisher, PhD – CSO